XML 51 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details Narrative)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 5 Months Ended 9 Months Ended
Dec. 26, 2017
USD ($)
Nov. 17, 2017
Nov. 07, 2017
Aug. 11, 2017
USD ($)
Jul. 09, 2017
USD ($)
Jun. 23, 2017
USD ($)
Apr. 30, 2018
Sep. 30, 2018
USD ($)
Products
$ / shares
shares
Sep. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Products
$ / shares
shares
Dec. 31, 2017
$ / shares
shares
Common stock issued | shares               6,218,980     6,218,980 6,000,000
Common stock par value per share | $ / shares               $ 0.001     $ 0.001 $ 0.001
Number of stock options issued to purchase common stock | shares                     135,000  
Payment of research and development expense               $ 1,544 $ 1,564 $ 3,067 $ 4,525  
Credit agreement term   10 years 10 years                  
Restricted Stock [Member]                        
Number of stock options issued to purchase common stock | shares                     218,980  
Imprimis [Member]                        
Common stock issued | shares               3,500,000     3,500,000  
Common stock par value per share | $ / shares               $ 0.001     $ 0.001  
Number of products | Products               2     2  
Related party transaction $ 50                      
Imprimis [Member] | Stock Option [Member]                        
Stock-based compensation expense                   70 $ 51  
Imprimis [Member] | Common Stock [Member]                        
Restricted stock award forfeited | shares                     20,000  
Percentage of restricted stock and option vested             100.00%          
Imprimis [Member] | Restricted Stock [Member]                        
Common stock issued | shares               1,500,000     1,500,000  
Number of restricted common stock issued for services | shares                     1,500,000  
Number of stock options issued to purchase common stock | shares                     130,000  
Stock-based compensation expense                   $ 856 $ 970  
Imprimis [Member] | Patents [Member]                        
Related party transaction                     $ 50  
Percentage of royalty fee                      
Eyemax [Member]                        
Related party transaction       $ 250                
Payment of research and development expense       250                
Sale of product expense       $ 500                
Related party transaction date       Aug. 11, 2017                
Percentage of royalty fee       10.00%                
Credit agreement term       10 years                
Andersen Pharma LLC [Member]                        
Related party transaction         $ 750              
Payment of research and development expense         750              
Sale of product expense         $ 750              
Related party transaction date         Jul. 09, 2017              
Percentage of royalty fee         50.00%              
Selenix LLC [Member]                        
Related party transaction           $ 1,500            
Payment of research and development expense           1,500            
Sale of product expense           $ 1,000            
Related party transaction date           Jun. 23, 2017            
Percentage of royalty fee           50.00%            
Credit agreement term           10 years